Literature DB >> 28434413

DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.

Antoni Gilabert-Perramon1, Josep Torrent-Farnell2, Arancha Catalan3, Alba Prat1, Manel Fontanet2, Ruth Puig-Peiró4, Sandra Merino-Montero5, Hanane Khoury6, Mireille M Goetghebeur7, Xavier Badia8.   

Abstract

OBJECTIVES: The aim of this study was to adapt and assess the value of a Multi-Criteria Decision Analysis (MCDA) framework (EVIDEM) for the evaluation of Orphan drugs in Catalonia (Catalan Health Service).
METHODS: The standard evaluation and decision-making procedures of CatSalut were compared with the EVIDEM methodology and contents. The EVIDEM framework was adapted to the Catalan context, focusing on the evaluation of Orphan drugs (PASFTAC program), during a Workshop with sixteen PASFTAC members. The criteria weighting was done using two different techniques (nonhierarchical and hierarchical). Reliability was assessed by re-test.
RESULTS: The EVIDEM framework and methodology was found useful and feasible for Orphan drugs evaluation and decision making in Catalonia. All the criteria considered for the development of the CatSalut Technical Reports and decision making were considered in the framework. Nevertheless, the framework could improve the reporting of some of these criteria (i.e., "unmet needs" or "nonmedical costs"). Some Contextual criteria were removed (i.e., "Mandate and scope of healthcare system", "Environmental impact") or adapted ("population priorities and access") for CatSalut purposes. Independently of the weighting technique considered, the most important evaluation criteria identified for orphan drugs were: "disease severity", "unmet needs" and "comparative effectiveness", while the "size of the population" had the lowest relevance for decision making. Test-retest analysis showed weight consistency among techniques, supporting reliability overtime.
CONCLUSIONS: MCDA (EVIDEM framework) could be a useful tool to complement the current evaluation methods of CatSalut, contributing to standardization and pragmatism, providing a method to tackle ethical dilemmas and facilitating discussions related to decision making.

Keywords:  Decision making; EVIDEM; Healthcare; Multi-criteria decision analysis

Mesh:

Year:  2017        PMID: 28434413     DOI: 10.1017/S0266462317000149

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  15 in total

Review 1.  HTA decision-making for drugs for rare diseases: comparison of processes across countries.

Authors:  Tania Stafinski; Judith Glennie; Andrea Young; Devidas Menon
Journal:  Orphanet J Rare Dis       Date:  2022-07-08       Impact factor: 4.303

Review 2.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 3.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

4.  Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis.

Authors:  Néboa Zozaya; Lucía Martínez-Galdeano; Bleric Alcalá; Jose Carlos Armario-Hita; Concepción Carmona; Jose Manuel Carrascosa; Pedro Herranz; María Jesús Lamas; Marta Trapero-Bertran; Álvaro Hidalgo-Vega
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807

5.  Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.

Authors:  Carina Schey; Maarten Jacobus Postma; Paul F M Krabbe; Olekdandr Topachevskyi; Andrew Volovyk; Mark Connolly
Journal:  Front Public Health       Date:  2020-05-08

6.  Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).

Authors:  Alberto Jiménez; Arantza Ais; Amélie Beaudet; Alicia Gil
Journal:  Orphanet J Rare Dis       Date:  2018-12-10       Impact factor: 4.123

7.  Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).

Authors:  Laura Guarga; Xavier Badia; Mercè Obach; Manel Fontanet; Alba Prat; Atonio Vallano; Josep Torrent; Caridad Pontes
Journal:  Orphanet J Rare Dis       Date:  2019-06-27       Impact factor: 4.123

8.  Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?

Authors:  Aleksandra Baran-Kooiker; Marcin Czech; Coen Kooiker
Journal:  Front Public Health       Date:  2018-10-15

Review 9.  Can reflective multicriteria be the new paradigm for healthcare decision-making? The EVIDEM journey.

Authors:  Mireille M Goetghebeur; Marjo S Cellier
Journal:  Cost Eff Resour Alloc       Date:  2018-11-09

10.  Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment.

Authors:  Jason C Hsu; Jia-Yu Lin; Peng-Chan Lin; Yang-Cheng Lee
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.